Schering appeal of FDA bioequivalence reg denied by Supreme Court.
SCHERING BIOEQUIVALENCE APPEAL REJECTED BY SUPREME COURT via an Oct. 2 denial of the company's petition for a writ of certiorari in the matter of Schering v. FDA concerning possible generic competition for the company's metered-dose albuterol inhaler Proventil. Schering-Plough challenged FDA's 1992 regulation implementing the Waxman/Hatch Act, which the company asserts unfairly broadened the ANDA provisions of the 1984 act.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth